Literature DB >> 29456612

The safety of regional citrate anticoagulation in renal replacement therapy.

Simon Hill1, Elaine Creighton1, Edward Walter1.   

Abstract

Entities:  

Year:  2018        PMID： 29456612      PMCID： PMC5810883          DOI： 10.1177/1751143717735749

Source DB:  PubMed          Journal:  J Intensive Care Soc        ISSN： 1751-1437


× No keyword cloud information.
  4 in total

1.  Evaluating the safety and efficacy of regional citrate compared to systemic heparin as anticoagulation for continuous renal replacement therapy in critically ill patients: A service evaluation following a change in practice.

Authors:  Roberta Borg; Debra Ugboma; Dawn-Marie Walker; Richard Partridge
Journal:  J Intensive Care Soc       Date:  2017-03-14

2.  Incidence and outcome of metabolic disarrangements consistent with citrate accumulation in critically ill patients undergoing continuous venovenous hemodialysis with regional citrate anticoagulation.

Authors:  Dmytro Khadzhynov; Christin Schelter; Ina Lieker; Alice Mika; Oliver Staeck; Hans-H Neumayer; Harm Peters; Torsten Slowinski
Journal:  J Crit Care       Date:  2013-11-11       Impact factor: 3.425

3.  Total-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients.

Authors:  Andreas Link; Matthias Klingele; Timo Speer; Ranja Rbah; Janine Pöss; Anne Lerner-Gräber; Danilo Fliser; Michael Böhm
Journal:  Crit Care       Date:  2012-05-29       Impact factor: 9.097

4.  Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study.

Authors:  Torsten Slowinski; Stanislao Morgera; Michael Joannidis; Thomas Henneberg; Reto Stocker; Elin Helset; Kirsti Andersson; Markus Wehner; Justyna Kozik-Jaromin; Sarah Brett; Julia Hasslacher; John F Stover; Harm Peters; Hans-H Neumayer; Detlef Kindgen-Milles
Journal:  Crit Care       Date:  2015-09-29       Impact factor: 9.097
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.